Safety of omacetaxine mepesuccinate (OM) subcutaneous (SQ) injection for the treatment of chronic myeloid leukemia (CML) patients (pts) resistant or intolerant to tyrosine kinase inhibitors (TKIs): Analysis of two phase II studies.
暂无分享,去创建一个
M. Baccarani | J. Cortes | J. Lipton | T. Masszi | M. Wetzler | M. Baer | F. Nicolini | N. Nanda | A. Benichou | D. Cram